Einat Brill Almon is SVP & Product Development at Protalix BioTherapeutics, Inc. (PLX). They have made 1 open-market trade across 1 company since 2008, most recently 2012-07-16.
CIK 0001385116
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PLX | 185,000 | $484K |
Shares reported on the most recent Form 4, priced at the 2012-07-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PLX | SELL · 10b5-1 | 2012-05-02 | 2012-05-04 | $7.13 | $1.2M | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2010-10-04 | 2010-10-06 | $9.10 | $637K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2010-09-03 | 2010-09-08 | $8.07 | $404K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2009-10-15 | 2009-10-19 | $9.41 | $847K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · 10b5-1 | 2009-07-06 | 2009-07-08 | $5.09 | $280K | -14.1% | +1.0% | +1.0% |
| PLX | SELL | 2009-05-18 | 2009-05-19 | $4.00 | $160K | -14.1% | +1.0% | +1.0% |
| PLX | SELL · Routine | 2008-05-12 | 2008-05-14 | $2.75 | $114K | -14.1% | +1.0% | +1.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.